SUBSCRIBERS

J&J drug unit to leverage Singapore's biotech hub

'Very lively biotech hub' spurs pharmaceutical arm's external collaborations

Annabeth Leow

Published Sun, Oct 28, 2018 · 09:50 PM

Singapore

JOHNSON & Johnson's (J&J) regional pharmaceutical head believes that Singapore offers innovation, research and development tie-up opportunities, even as wider insurance coverage in the Asia-Pacific is expected to fuel growth for drugmakers.

Ong Ai Hua, the group chairman for Janssen Asia Pacific, the pharmaceutical arm of J&J, told The Business Times that "our focus in Singapore is on innovation - not so much on manufacturing".

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes